New Horizon for Treatment of Inherited Retinal Dystrophy

By: SMi Conferences
 
LONDON - Oct. 11, 2018 - PRLog -- Over the past twelve months there has been significant advancements in cell gene therapy for inherited retinal dystrophy, with an FDA approval of Spark Therapeutics' Voretigene – the first gene therapy approved in ophthalmology. The company's Clinical Ophthalmic Lead, Daniel Chung will be speaking at the 2nd annual Ophthalmic Drugs Conference in London on 26th November, where he will share his experiences on the development of Voretigene and its success. He will also discuss upcoming gene therapy trials and market access difficulties.

Daniel will be joined by a senior panel of big pharma and ophthalmic organisations to discuss the latest developments and innovations in ocular gene editing including:

Alan Stitt, Dean of Innovation and Impact, Queen's University Belfast
Mitchell de long
, Vice President, Chemistry, Aerie Pharmaceuticals
Naj Sharif
, Executive Director and Head, Global Alliances & External Research, Santen
Majid Anderesi
, Associate Group Clinical Director, Ophthalmology, Roche
Caroline Barelle
, CEO, Elasmoge
Victor Chong
, Global Head of Ophthalmology, Boehringer Ingelheim
Aniz Girach
, Chief Medical Officer, Nightstar Therapeutics
Peter Morgan-Warren
, Medical Assessor, Licensing Division, MHRA
David Silverman
, Clinical Director, Ophthalmology, Roche

Programme highlights include recent advances in the treatment of glaucoma; recent applications of artificial intelligence in drug discovery and biomarkers and surrogate end-points from a regulatory perspective.

https://www.smi-online.co.uk/pharmaceuticals/uk/Opthalmic...

Sponsors: Aero Pump | Experimentica | Nemera

---end---

Contact
Neill Howard
***@smi-online.co.uk
02078276164
End
Source:SMi Conferences
Email:***@smi-online.co.uk Email Verified
Tags:Ocology, Ophthalmic, Glaucoma
Industry:Health
Location:London City - London, Greater - England
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share